JMT103

Phase 3Small molecule

SShanghai JMT-Bio Inc.

JMT103 is one of 59 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyUnknown status

Malignant Solid TumorsNot yet recruiting

Efficacy and SafetyPreclinical

Unknown status

Malignant Solid TumorsPhase 3

Not yet recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 2

HLX10

Shanghai Henlius Biotech

Phase 3

2 3

NTQ5082

NNanjing Chia-tai Tianqing Pharmaceutical

Phase 3

1 4

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 3

1 5

TLL-018

HHangzhou Highlightll Pharmaceutical Co., Ltd

Phase 3

1 6

NVX-Cov2705

Sanofi

Phase 3

1 7

JMT103

SShanghai JMT-Bio Inc.

Phase 3

4 8

IBI302

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 9

IN-B00009

HHK inno.N Corporation

Phase 3

1 10

Esoduo

Chong Kun Dang Pharmaceutical

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Not yet recruiting

Malignant Solid Tumors

NCT06221072

Clinical

Trials by Indication[1]

Osteoporosis2 trials

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT05397938·231 enrolled

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT05278338·200 enrolled

Malignant Solid Tumors1 trial

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06221072·1,360 enrolled

Hypercalcemia1 trial

A Phase I/II, Single Arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory Hypercalcemia of Malignancy

Terminated·SShanghai JMT-Bio Inc.·Preclinical·NCT04198480·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for JMT103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JMT103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JMT103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai JMT-Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai JMT-Bio Inc.

JMT103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Osteoporosis2 trials

Malignant Solid Tumors1 trial

Hypercalcemia1 trial

References

Drug Info

Quick Facts

Related News